Amgen Inc. has confirmed it will purchase the 49% of shares in its Japanese joint venture Amgen Astellas BioPharma KK currently held by Astellas Pharma Inc., effective 1 April, converting the Tokyo-based operation into a wholly owned affiliate.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?